C

Corline Biomedical AB
STO:CLBIO

Watchlist Manager
Corline Biomedical AB
STO:CLBIO
Watchlist
Price: 17 SEK -1.16% Market Closed
Market Cap: 416.3m SEK

Corline Biomedical AB
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Corline Biomedical AB
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
C
Corline Biomedical AB
STO:CLBIO
Operating Income
-kr13.8m
CAGR 3-Years
N/A
CAGR 5-Years
-8%
CAGR 10-Years
-14%
Calliditas Therapeutics AB
STO:CALTX
Operating Income
-kr353.1m
CAGR 3-Years
14%
CAGR 5-Years
-60%
CAGR 10-Years
N/A
Orexo AB
STO:ORX
Operating Income
-kr145.9m
CAGR 3-Years
6%
CAGR 5-Years
N/A
CAGR 10-Years
-8%
Camurus AB
STO:CAMX
Operating Income
kr927.2m
CAGR 3-Years
198%
CAGR 5-Years
N/A
CAGR 10-Years
29%
S
Swedencare AB (publ)
STO:SECARE
Operating Income
kr171.2m
CAGR 3-Years
85%
CAGR 5-Years
32%
CAGR 10-Years
N/A
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Operating Income
-kr28.9m
CAGR 3-Years
31%
CAGR 5-Years
17%
CAGR 10-Years
N/A
No Stocks Found

Corline Biomedical AB
Glance View

Market Cap
416.3m SEK
Industry
Pharmaceuticals

Corline Biomedical AB engages in the research, development, and commercialization of heparin based solutions. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2015-06-03. The company develops, manufactures and markets heparin-based solutions to improve kidney transplantation, cell therapies and applications in regenerative medicine.

CLBIO Intrinsic Value
26.47 SEK
Undervaluation 36%
Intrinsic Value
Price
C

See Also

What is Corline Biomedical AB's Operating Income?
Operating Income
-13.8m SEK

Based on the financial report for Sep 30, 2025, Corline Biomedical AB's Operating Income amounts to -13.8m SEK.

What is Corline Biomedical AB's Operating Income growth rate?
Operating Income CAGR 10Y
-14%

Over the last year, the Operating Income growth was -44%.

Back to Top